ER negative

Pre-treatment histogram analysis of MTRasym values derived from APTWI provides significant predictive value for pCR post-NAC in breast cancer. The combined diagnostic model incorporating APTWI with ER and HER2 expression status further enhances diagnostic performance.

BRCA1 mutation carriers face a higher risk of developing ER negative metachronous CBC, in ER negative primary tumor. These results support genetic counseling and risk-reducing strategies, including prophylactic mastectomy, for BRCA1 mutation carriers.

Immunofluorescence analysis of tumor tissues post-treatment revealed the localized induction of thermal stress and upregulation of Heat Shock Protein 70 (HSP-70), a biomarker linked to enhanced immune cell infiltration and activation within the tumor microenvironment. Overall, this study presents a methodical effort to explore the effectiveness of cobalt-zinc-ferrite nanoprobe for chemo-magnetic hyperthermia effects that can be used for efficient, patient-specific, targeted, controlled anticancer therapy through chemodynamic-magnetic-thermal synergistic therapy.

We identified unique periods of susceptibility to NO2 and PM2.5 for breast cancer risk by ER status.

Our study suggests that postoperative RT is associated with improved survival in most DCIS patients. The nomograms showed good performance in predicting the DSS and DFS of DCIS patients, and our online tool well visualized the DSS and DFS prediction to support clinical decision-making.

In conclusion, the present investigation reveals a noteworthy correlation between elevated levels of MRP2 protein in CTCs and TNBC. This finding deepens our understanding of the molecular mechanisms that contribute to the metastasis of breast cancer and provides a scientific basis for predicting treatment outcomes in breast cancer patients exhibiting elevated levels of MRP2 protein expression.

In HER2-low breast cancer, TLSs were associated with higher histological grade, the presence of DCIS, absence of lymphovascular invasion, as well as expression of ER negative, PR negative, HER2 2 + , high K-i67, and triple-negative breast cancer. Additionally, the clinical prognosis value of TLSs (such as DFS) exhibited a correlation with the patient's age.

P=N/A, N=130, Recruiting, Jewish General Hospital | Trial completion date: Jun 2023 --> Dec 2027 | Trial primary completion date: Jun 2022 --> Dec 2027

These findings suggest that the anti-breast cancer effect of DOT1L inhibition is mediated by multiple mechanisms, including activation of innate immune signaling.

Remarkably, the LCOR-ERα disruption converts HR+BC immune-cold tumors into immune-hot tumors responsive to ICB by increased antigen presentation machinery (APM) expression, immune infiltration, T cell recognition and mediated killing. In conclusion, ERα inhibition and the disruption of LCOR to ERα represent a novel therapeutic strategy and an opportunity to elicit immunotherapeutic benefit in HR+BC patients.

We confirmed that these organoids are unresponsive to estrogen, can self-renew, and express the stem/progenitor marker CD44. In addition, we observed that these organoids contain outgrowths that resemble the mature ductal and lobular units of the mammary gland, thus making it a suitable model system to study how cancer develops in ER/PR/HER2-negative mammary cells that carry a BRCA1 germline mutation.

These findings advance our understanding of genetic susceptibility to different cancers. Future work in larger, more diverse GWAS, coupled with more comprehensive annotation atlases, is essential to expand upon and validate our results.